Products & Services · Total revenues
OXLUMO — Total revenues
Alnylam Pharmaceuticals OXLUMO — Total revenues increased by 3.4% to $51.32M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.9%, from $42.09M to $51.32M. Over 4 years (FY 2021 to FY 2025), OXLUMO — Total revenues shows an upward trend with a 33.9% CAGR.
Analysis
Metric ID:
alny_segment_oxlumo_total_revenuesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.34M | $14.89M | $19.21M | $14.59M | $14.94M | $16.43M | $23.83M | $24.16M | $24.21M | $28.74M | $32.73M | $42.65M | $40.61M | $40.22M | $43.57M | $42.09M | $46.87M | $52.83M | $49.65M | $51.32M |
| QoQ Change | — | -8.9% | +28.9% | -24.1% | +2.4% | +10.0% | +45.0% | +1.4% | +0.2% | +18.7% | +13.9% | +30.3% | -4.8% | -1.0% | +8.3% | -3.4% | +11.4% | +12.7% | -6.0% | +3.4% |
| YoY Change | — | — | — | — | -8.6% | +10.3% | +24.1% | +65.6% | +62.1% | +74.9% | +37.3% | +76.5% | +67.7% | +40.0% | +33.1% | -1.3% | +15.4% | +31.4% | +13.9% | +21.9% |
Range$14.59M – $52.83M
CAGR+27.2%
Avg YoY Growth+35.3%
Median YoY Growth+32.2%
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's oxlumo — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported oxlumo — total revenues of $51.32M in Q1 2026.
- How has Alnylam Pharmaceuticals's oxlumo — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's oxlumo — total revenues increased by 21.9% year-over-year, from $42.09M to $51.32M.
- What is the long-term trend for Alnylam Pharmaceuticals's oxlumo — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's oxlumo — total revenues has grown at a 33.9% compound annual growth rate (CAGR), from $59.59M to $191.44M.